Dinamika pendapatan YoY sajrone rolas wulan kepungkur: Virax Biolabs Corp (VRAX)

The 12-month YoY sales growth chart demonstrates the effectiveness of competent management within the rapid diagnostics niche amid cyclical revenue fluctuations for Virax Biolabs Group (VRAX). Current revenue relies on the inertia of local epidemics, creating volatility without long-term stability. The value of 96.00 reflects the latest metric, highlighting the potential of innovative portable laboratories that allow the company to exercise pricing power.
Virax Biolabs (VRAX) - rincian metrik lan laporan keuangan

This indicator measures the daily change in aggregate revenue over a rolling year, allowing investors to filter out short-term volatility and assess the actual scalability of the business. By analyzing the year-over-year product sales dynamics for TTM, one can determine the commercialization efficiency of Virax Biolabs Group (VRAX) diagnostic systems for detecting viral infections and evaluate the demand stability for their immunological tests.